Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Rotavirus strain trends during the postlicensure vaccine era: United States, 2008-2013
Journal of Infectious Diseases, Volume 214, No. 5, Year 2016
Notification
URL copied to clipboard!
Description
Background. Group A rotaviruses (RVA) are a significant cause of pediatric gastroenteritis worldwide. The New Vaccine Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and emergency departments at 3-7 geographically diverse sites in the United States since 2006. Methods. Over 6 consecutive years, from 2008 to 2013, 1523 samples from NVSN sites that were tested positive by a Rotaclone enzyme immunoassay were submitted to the Centers for Disease Control and Prevention for genotyping. Results. In the 2009, 2010, and 2011 seasons, genotype G3P[8] was the predominant genotype throughout the network, with a 46%-84% prevalence. In the 2012 season, G12P[8] replaced G3P[8] as the most common genotype, with a 70% prevalence, and this trend persisted in 2013 (68.0% prevalence). Vaccine (RotaTeq; Rotarix) strains were detected in 0.6%-3.4% of genotyped samples each season. Uncommon and unusual strains (eg, G8P[4], G3P[24], G2P[8], G3P[4], G3P[6], G24P[14], G4P[6], and G9P[4]) were detected sporadically over the study period. Year, study site, and race were found to be significant predictors of genotype. Conclusions. Continued active surveillance is needed to monitor RVA genotypes in the United States and to detect potential changes since vaccine licensure. © The Author 2016.
Authors & Co-Authors
Bowen, Michael D.
United States, Atlanta
Centers for Disease Control and Prevention
Mijatovic-Rustempasic, Slavica
United States, Atlanta
Centers for Disease Control and Prevention
Esona, Mathew Dioh
United States, Atlanta
Centers for Disease Control and Prevention
Gautam, Rashi
United States, Atlanta
Centers for Disease Control and Prevention
Sturgeon, Michele M.
United States, Atlanta
Centers for Disease Control and Prevention
Azimi, Parvin H.
United States, Oakland
Ucsf Benioff Children's Hospital Oakland
Baker, Carol J.
United States, Houston
Texas Children's Hospital
United States, Houston
Baylor College of Medicine
Bernstein, David Isaac
United States, Cincinnati
Cincinnati Children's Hospital Medical Center
Chappell, James D.
United States, Nashville
Vanderbilt University Medical Center
Edwards, Kathryn M.
United States, Nashville
Vanderbilt University Medical Center
Englund, Janet A.
United States, Seattle
Seattle Children's Hospital
Halasa, Natasha B.
United States, Nashville
Vanderbilt University Medical Center
Harrison, Christopher J.
Unknown Affiliation
Klein, Eileen J.
United States, Seattle
Seattle Children's Hospital
McNeal, Monica Malone
United States, Cincinnati
Cincinnati Children's Hospital Medical Center
Selvarangan, Rangaraj
Unknown Affiliation
Szilâgyi, Peter G.
United States, Los Angeles
University of California, Los Angeles
Weinberg, Geoffrey A.
United States, Rochester
University of Rochester School of Medicine and Dentistry
Parashar, Umesh D.
United States, Atlanta
Centers for Disease Control and Prevention
Payne, Daniel C.
United States, Atlanta
Centers for Disease Control and Prevention
Statistics
Citations: 55
Authors: 20
Affiliations: 9
Identifiers
Doi:
10.1093/infdis/jiw233
ISSN:
00221899
Research Areas
Genetics And Genomics
Study Design
Cross Sectional Study